Product Reports Resources Pricing Login Book a demo

Alimera Sciences

Biotech & Life Sciences · Alpharetta, United States · Founded 2003 · IPO 2010

Develops and commercializes prescription ophthalmic pharmaceuticals

Valuation $360M
Revenue $105M
EBITDA $6.8M

Talent graph

Alimera Sciences's talent

Book a demo to see the people
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia 4 alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

5 investors on Alimera Sciences's cap table

Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.

Series A 4 investors entered at this stage
Domain Associates
Scale Venture Partners
Intersouth Partners
Polaris Partners
Series B+ 1 investor entered at this stage

Global footprint

Where Alimera Sciences has talent and traffic

Workforce by country
16 countries with
team presence
🇺🇸 United States28.9%
🇬🇧 United Kingdom27.2%
🇵🇹 Portugal10.9%
🇩🇪 Germany10.1%
🇮🇪 Ireland3.6%
Top 5 of 16 shown
Web traffic by country
20 monthly visits
across markets
🇺🇸 United States0%
Top 1 markets shown

Patent intelligence

$2M patent portfolio · 3 active families

Estimated portfolio value
$2M
0.55% of market cap · 38.8× smaller than top peer KalVista Pharmaceuticals ($77M)
3 active patent families
Where Alimera Sciences innovates After treatmentConjunctivitidesCorticosteroid treatmentDiseaseImplant

Where Alimera Sciences concentrates vs peers

Each axis is a top-10 topic across Alimera Sciences and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Alimera Sciences

An AI-synthesized read of the highest-engagement posts about Alimera Sciences on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Alimera Sciences on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.